Fulgent Genetics

Fulgent Genetics is an El Monte, California-based clinical diagnostics company that runs a high-complexity molecular laboratory alongside a growing anatomic pathology business built through the acquisitions of Bako Diagnostics and StrataDx. Its tests span hereditary cancer, reproductive health, rare disease and oncology, and the company also sells a therapeutic development service using a nanoencapsulation drug-delivery platform. Fulgent reported third-quarter 2026 revenue of $90.4 million, up 8% year over year, with anatomic pathology revenue up 57% to $40.9 million, and reaffirmed full-year 2026 revenue guidance of $330 million to $340 million while improving its non-GAAP loss outlook. The company ended the quarter with roughly $652 million in cash, cash equivalents, restricted cash and marketable securities, and has repurchased more than 7.5 million shares since its buyback programme began in 2022.